India's cancer care system is facing a growing challenge as shortages of two essential chemotherapy drugs Cisplatin and Carboplatin continue to impact treatment schedules at hospitals across the country. The shortage is forcing oncologists to make difficult decisions, including delaying treatments, adjusting dosages, and turning to more expensive alternatives that may not offer the same level of effectiveness.
The targeted therapy, marketed as Elahere, has shown improved survival rates and better quality of life in women with advanced ovarian cancer that no longer responds to platinum-based chemotherapy.
